## Tenecteplase: Structure and Clinical Advantage **Key Point:** Tenecteplase (TNK-tPA) is a **genetically engineered variant** of alteplase with three point mutations that confer superior pharmacokinetic and pharmacodynamic properties. ### Structural Modifications of Tenecteplase | Modification | Location | Effect | Clinical Benefit | |---|---|---|---| | **T103N** (Threonine → Asparagine) | Finger domain | Reduced clearance by hepatic receptors | **Longer half-life (17 min vs 5 min)** | | **N117Q** (Asparagine → Glutamine) | Finger domain | Enhanced fibrin binding | Improved fibrin selectivity | | **KHRR296-299AAAA** | Kringle-2 domain | Reduced binding to non-fibrin targets | Decreased systemic fibrinolysis | **High-Yield:** The T103N substitution is the **primary modification** responsible for TNK-tPA's longer half-life, allowing **single-bolus administration** (vs. infusion for alteplase) — a major practical advantage in acute MI. **Clinical Pearl:** Tenecteplase is **more fibrin-selective** than alteplase due to reduced clearance and enhanced fibrin binding. This translates to lower rates of non-target plasminogen activation and reduced systemic bleeding risk — particularly important in acute ischemic stroke. **Mnemonic:** **TNK = Three Notable Kinetic changes** — T103N (half-life ↑), N117Q (fibrin binding ↑), KHRR→AAAA (systemic lysis ↓).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.